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Acquired vorinostat resistance shows partial cross-resistance
to ‘second-generation’ HDAC inhibitors and correlates
with loss of histone acetylation and apoptosis
but not with altered HDAC and HAT activities
Konstantin J. Dedesa, Ioannis Dedesa, Patrick Imescha, Andre´ O. von Buerenb,
Daniel Finka and Andre´ Fediera
Histone deacetylase (HDAC) inhibitors such as vorinostat
(suberoylanilide hydroxamic acid), valproic acid,
romidepsin (FK-228), and LBH589 comprise a relatively
new class of potent anticancer agents. This study provides
evidence for the potential of vorinostat to cause acquisition
of multidrug resistance protein-independent resistance in
HCT116 colon tumor cells. This acquired resistance is
moderate (two-fold to three-fold), is nonreversible, and
correlates with the loss of responses typically seen with
HDAC inhibitors, that is the loss of acetylation of the
histones H2A, H2B, H3, and H4, the loss of the G2/M
checkpoint activation, and the loss of caspase 3-dependent
and caspase 7-dependent apoptosis. This acquired
resistance also associates with cross-resistance to
the hydroxamate-class (LBH589 and JNJ26481585)
and to the aliphatic acid-class (valproic acid) HDAC
inhibitors but not to the benzamide-class (MGCD0103)
and the cyclic peptide-class (romidepsin) HDAC inhibitors.
The acquired HDAC inhibitor resistance described here
is not a result of altered HDAC and histone
acetyltransferase activities and differs from that previously
reported for romidepsin. Anti-Cancer Drugs 20:321–333
c 2009 Wolters Kluwer Health | Lippincott Williams
& Wilkins.
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Introduction
Vorinostat (suberoylanilide hydroxamic acid, SAHA)
belongs to the continuously growing class of histone
deacetylase (HDAC) inhibitors [1–3]. Preclinical studies
with vorinostat have shown that its antiproliferative
effects are associated with activation of the G2/M
cell cycle checkpoint and upregulation of p21, with
downregulation of cyclin D1, and with acetylation of
numerous transcription factors (e.g. p53) and other
proteins (e.g. HSP90, tubulin) [1]. In general, HDAC
inhibitors result in the accumulation of acetylated
histones and of nonhistone proteins, and many of them
exert strong antineoplastic activity. They also alter the
gene expression pattern and thereby cause cell cycle
arrest and apoptosis preferentially in tumor cells [4–8].
Resistance to an anticancer treatment, either present
intrinsically in tumor cells or acquired during a treatment,
is a frequently observed and persistent problem during
cancer treatment. Acquired resistance is a particular
problem, because tumors not only become resistant to
the drugs originally used to treat them, but may also
become cross-resistant to other drugs with different
mechanisms of action. Mechanisms of resistance to
HDAC inhibitors and their therapeutic implications
have recently been reviewed [9]. In addition, the
potential of HDAC inhibitors to cause drug resistance
in tumor cells has recently become apparent. The
HDAC inhibitor romidepsin (FK-228 or depsipeptide)
has been shown to cause transient resistance by the
reversible induction of multidrug resistance protein
(MDR) expression in tumor cells and is to date the only
HDAC inhibitor known to be substrate for multidrug
resistance transporters [10,11]. Recently, we reported the
generation of two MDR-independent, vorinostat-resistant
sublines [12], these were the DNA mismatch repair
(MMR)-proficient HCT116ch3 colorectal adenocarcinoma
cell line (supplemented with chromosome 3 harboring
the wild-type copy of the MLH1 gene to compensate
for the MLH1 gene truncating mutation present in the
parental MMR-deficient HCT116 cell line) and the
MMR-deficient HCT116ch2 cell line (supplemented
with the MLH1-irrelevant chromosome 2 for chromo-
some balance). Although a relationship between
MLH1 expression and histone acetylation has been
suggested [13,14], this vorinostat-induced resistance
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was independent of the presence or absence of MLH1
protein. Noteworthy, these vorinostat-resistant sublines
were cross-resistant to the HDAC inhibitor trichostatin A,
but retained sensitivity to non-HDAC inhibitor-type
anticancer agents.
Using the parental HCT116 colorectal adenocarcinoma
cell line, this study was designed to (i) elucidate in more
detail the mechanism(s) behind resistance induction by
vorinostat, (ii) investigate a possible cross-resistance to
some ‘second-generation’ HDAC inhibitors, and (iii) exclude
a possible effect of the presence of the extra chromosome
in the respective cell lines on this type of acquired
vorinosat resistance. Further evidence is provided that
in HCT116 tumor cells vorinostat can lead to a multi-
drug resistance transporter-independent acquisition of
resistance. This resistance correlates with the losses of
histone acetylation, cell cycle attenuation, and apoptosis,
but does not associate with altered HDAC and histone
acetyltransferase (HAT) activities.
Materials and methods
Drugs and chemicals
Vorinostat (SAHA; Alexis Biochemicals, Lausen, Switzerland)
and valproic acid (VPA; Sigma, Buchs, Switzerland)
were purchased. LBH589 (Novartis Pharmaceutical Inc.,
Cambridge, Massachusetts, USA), MGCD0103 (ALTANA
Pharma-Nycomed, Byk-Gulden Street 2, Konstanz,
Germany), and JNJ26481585 (J&J Pharmaceutical
Research & Development, Beerse, Belgium) were provided.
Romidepsin (FK-228, depsipeptide) was provided by
Gloucester Pharmaceuticals (Cambridge, Massachusetts,
USA). Stock solutions (stored at – 201C) were prepared
in dimethyl sulfoxide (vorinostat, LBH589, MGCD0103,
JNJ26481585, romidepsin) or in H2O (VPA).
Cell culture and generation of
vorinostat-resistant sublines
An HCT116 human colorectal adenocarcinoma cell line
(American Type Culture Collection, ATCC CCL 247;
Rockville, Maryland, USA) and a HeLa cervical carcinoma
cell line (provided by Dr G. Marra, Institute of Molecular
Cancer Research, University of Zurich, Switzerland) were
used. Both cell lines were cultured in IMDM-21980
(Invitrogen, Basel, Switzerland) containing 10% fetal calf
serum (Oxoid, Basel, Switzerland) at 371C and in an
atmosphere with 5% CO2 and 95% humidity.
The respective sublines (hereafter designated as HCT116/
VOR or HeLa/VOR) were generated by stepwise exposures
of the cell lines to increasing concentrations of vorinostat,
starting with 2 mmol/l of vorinostat for both cell lines.
Briefly, 100 000 cells seeded in cell culture flasks were
treated with vorinostat on the next day. Forty-eight hours
later, the vorinostat-containing medium was exchanged
for vorinostat-free medium, followed by incubation of
the cells for another 6 days to allow recovery of the
surviving cells and by harvesting the cells by trypsini-
zation. Cells were then transferred into new flasks,
expanded to confluence, harvested, and reseeded
(100 000) in flasks. On the next day, cells were treated
with vorinostat and subjected to medium exchange,
recovery, and harvesting as described. This protocol was
repeated seven times, and for each cycle the concentra-
tion of vorinostat was increased, resulting in a 14-fold
total increment for HCT116 (28 mmol/l) and a 35-fold for
HeLa cells (70 mmol/l). A further increase in the selection
pressure beyond these apparently maximal vorinostat
concentrations failed to produce sufficient surviving
cells for cell culture expansion.
The principle of selection was the clonal growth in the
presence of increasing concentrations of vorinostat,
on the basis that cells are altered by chronic vorinostat
exposure in a way they acquire new features in an
irreversible manner. The growth rates of the cell lines and
the respective sublines were calculated from the doubling
times from one passage to the subsequent, averaged for
a period of 2 months, and compared with one another.
The level of resistance was determined immediately after
the cells have been expanded to confluency after the
last cycle by the clonogenic assay [these are the half
maximal inhibitory concentration (IC50) values presented
throughout the study] and was periodically monitored by
the clonogenic assay against the parental cell line. The
level of resistance was maintained over a period of at
least 6 months even when cultured in the absence of the
selection pressure of vorinostat. When seeded sparsely
on culture plates, the cell lines and the sublines formed
well-defined individual colonies.
Drug sensitivity assays
Sensitivity of cells to the HDAC inhibitors tested here
was assessed by clonogenic and growth inhibition assays.
In a typical clonogenic assay setting, 600 cells in medium
were plated onto 60-mm cell culture dishes, followed by
drug addition on the next day. Cells were cultured for
another 7 days to allow colony formation, fixed with
25% acetic acid in ethanol, and stained with Giemsa.
Colonies of at least 50 cells were scored. Each experiment
was carried out at least three times in triplicate cultures.
The relative colony formation (percentage of clonogenic
survival) was plotted against the drug concentrations,
and the IC50 concentrations were calculated by linear
extrapolation. For growth inhibition, 50 000 cells were
plated onto 35-mm culture dishes and treated with
vorinostat (1, 2, 5, 10 mmol/l). Cells were harvested by
trypsinization at multiples of 24 h after treatment and
counted using a hematocytometer. In addition, Trypan
blue-inclusion was used to monitor drug-induced necrosis.
Cells were treated for 24 h with 5, 10, or 20 mmol/l of
vorinostat, harvested by trypsinization after another 24-h
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incubation, and resuspended in PBS containing 0.2%
Trypan blue. Cells were inspected and categorized using
a hematocytometer. Vital (Trypan blue-excluding) cells
appear bright, and necrotic (Trypan blue-including) cells
appear blue under the microscope.
Microscopy
Cells (200 000) were plated onto 35-mm cell culture
dishes, grown to 70% confluence, and then grown for
another 24 h without (controls) or with 10 mmol/l of
vorinostat. Bright-field images were taken using a microscope
(Leica DM-IL; Leica Microsystems, Heerbrugg, Switzer-
land) equipped with a photocamera (Leica DC-300F;
Leica Microsystems).
Immunoblot analysis
All the experiments for immunoblot analysis and for
cell cycle and apoptosis analyses (described below)
were carried out the way that all the cultures were
subconfluent at the time of analysis to avoid undesired
effects because of, for example, contact inhibition.
Immunoblot analysis was used to monitor protein
expression and posttranslational modifications of pro-
teins (phosphorylation, acetylation). After the cells have
grown to 70% confluence in 60-mm dishes, they were
treated with HDAC inhibitors and collected at various
time points after treatment, washed in PBS, and lysed for
immunoblot analysis performed following standard
protocols. Briefly, 20-mg protein was separated using
10 or 15% sodium dodecyl sulfate polyacrylamide gel
electrophoresis, followed by the blotting onto a poly-
vinylidene difluoride membrane (Amersham Biosciences,
Otelfingen, Switzerland), and the detection by the
specific primary antibodies and the respective secondary,
horseradish peroxidase-conjugated anti-mouse (M15345;
Transduction Laboratories, Lexington, Kentucky, USA) or
anti-rabbit (7074; Cell Signaling; BioConcept, Allschwil,
Switzerland) antibodies. The following primary antibodies
were used (Cell Signaling, if not specified otherwise):
acetyl-H2A (2576), acetyl-H2B (2575), acetyl-H3 (9671),
acetyl-H4 (2594), acetyl-p53 (ab37318; Abcam, Cambridge,
UK), acetyl-tubulin (T-6793; Sigma), acetyl-HSP90
(ABIN233817; antibodies-online, Aachen, Germany),
MDR (sc-13131; Santa Cruz Biotechnology Inc., Santa
Cruz, California, USA), multidrug resistance-associated
protein 1 (MRP-1; sc-18835; Santa Cruz Biotechnology),
HDAC1 (2062), HDAC2 (05-815; Upstate, Lake Placid,
New York, USA), HDAC3 (2632), HDAC4 (2072),
HDAC5 (2082), HDAC6 (2162), HDAC7 (2862), full-length
and cleaved caspase-3 (9662, 9661), full-length and
cleaved caspase-7 (9492, 9491), full-length and cleaved
PARP-1 (9542, 9541), Bax (2772), Bak (3792), Bid
(2002), Bim (4582), Bik (4592), Bok (4521), Bcl-2
(2872), Bcl-xL (2762), survivin (Pro-2233; ProSci Inc.,
Poway, California, USA), XIAP (2042), Mcl-1 (4572),
p21 (2946), p27 (2552), p53 (sc-6243; Santa Cruz
Biotechnology), cyclin B1 (4135), cyclin D1 (2926),
cyclin D3 (2936), cyclin E2 (4132), thioredoxin (2285),
thioredoxin-binding protein 2/VDUP-1 (sc-33099; Santa
Cruz Biotechnology or 40-3700; ZYMED, Invitrogen,
Carlsbad, California, USA), HSP90 (sc-7947; Santa Cruz
Biotechnology), and phospho-HSP27 (2401). Anti-mouse
b-actin (A5441; Sigma) or anti-rabbit b-tubulin (2148,
Cell Signaling) was used as sample loading controls.
Complexes were visualized by enhanced chemiluninescence
(Amersham Biosciences) and autoradiography.
HDAC immunoprecipitation and determination
of HDAC and HAT activities
Immunoprecipitation of HDAC1 (2062; Cell Signaling),
HDAC2 (05–814; Upstate), HDAC3 (05–813; Upstate),
and HDAC6 (07–732; Upstate) was done following
standard protocols provided by the manufacturers from
total cell extracts (lysates) of the vorinostat-sensitive
HCT116 cell line and the vorinostat-resistant HCT116/
VOR subline using Protein A agarose beads (16–266;
Upstate) and the respective immunoprecipitation-qualified
antibodies. Nuclear extracts of the sensitive HCT116
cell line and the resistant HCT116/VOR subline were
produced using the TransFactor Extraction Kit and
following the manufacturer’s protocol (631921, Clontech,
Takara Bio Europe, Saint-Germain-en-Laye, France).
Protein concentration of nuclear and total cell extracts
and the samples was determined by the BCA Protein
Assay Kit (23227; Pierce, Perbio Science, Lausanne,
Switzerland).
The HDAC and HAT enzymatic activities were deter-
mined in total or nuclear cell extracts using the colori-
metric HDAC activity assay Kit (ab1432, Abcam), the
fluorometric HDAC assay Kit (17–356; Upstate), and the
fluorescent HAT activity assay kit (56100, Active Motif
Europe, Rixensart, Belgium). Measurements were made
with a SpectraFluor Plus Reader (Tecan AG, Hombrech-
tikon, Switzerland). The assays, including all standard
assays, were performed according to the protocols
provided by the manufacturers. All the activity assays
were performed in two independent settings under
conditions where neither the sample enzymatic activity,
the substate, nor the assay incubation time were rate
limiting. Enzymatic activities were standardized, that is,
expressed as units or counts per amount of protein.
Cell cycle and apoptosis analyses by flow cytometry
Analyses of cell cycle profiles [propidium iodide (PI)
incorporation in the DNA] and apoptosis (TUNEL DNA
fragmentation) were performed by flow cytometry on a
FACSCalibur flow cytometer (BD Biosciences; Allschwil,
Switzerland) with CELLQuest software (BD Biosciences).
Data analyses for cell cycle distribution and apoptosis
were performed on linear PI histograms using the
mathematical software ModFit LT 2.0 (Verity Software
House; Topsham, Maine, USA). For sample preparation,
synchronized (2mmol/l hydroxyurea for 14 h) cells were
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grown to 70% confluence in 60-mm dishes and treated
with 15 mmol/l of vorinostat. At different time points,
adherent and floating cells were harvested, washed in
PBS, and fixed with ice-cold 70% ethanol. For cell cycle
analysis, cells were washed in PBS after removal of the
ethanol by centrifugation, stained in 1ml staining
solution (50 mg/ml of PI and 100U/ml RNAse A in PBS)
by incubation at room temperature for 45min in the
dark, and then washed in PBS. For TUNEL apoptosis
analysis, following ethanol removal the cells were washed
in PBS, resuspended in the TUNEL reaction-mix, and
incubated at 371C for 90min according to the manu-
facturer’s protocol (In Situ Cell Death Detection Kit,
Fluorescein; Roche Diagnostics, Rotkreuz, Switzerland).
Statistical analysis
The mean±SD values were calculated. A P value of
less than 0.05 is considered statistically significant
(paired, two-tailed Student’s t-test).
Results
Generation of the vorinostat-induced and stable
vorinostat-resistant HCT116 sublines
A vorinostat-induced (resistant) subline (hereafter
referred to as HCT116/VOR) was generated by step-
wise exposures of the parental HCT116 human colorectal
adenocarcinoma cell line to increasing concentrations
of vorinostat. Clonogenic assay data showed that
the vorinostat-induced subline was two-fold resistant
(P<0.001) to vorinostat as compared with the corres-
ponding parental HCT116 cell line (Fig. 1a). The
respective IC50 values were 1.32±0.14 mmol/l for the
resistant HCT116/VOR subline and 0.67±0.08 mmol/l
for the (sensitive) parental HCT116 cell line. The
resistant subline exhibited a growth rate comparable
with that of the parental HCT116 cell line, as the
doubling times were 22.6±0.9 h for HCT116 and
23.5±1.2 h for HCT116/VOR. Similarly, vorinostat
inhibited growth of the vorinostat-resistant HCT116/
VOR subline less efficiently than the vorinostat-sensitive
HCT116 cell line (Fig. 1b). For instance, at 96 h after
treatment the respective values were five-fold (1 mmol/l
vorinostat), eight-fold (2mmol/l), four-fold (5 mmol/l),
and 11-fold (10 mmol/l). This HCT116/VOR subline
maintained resistance to vorinostat for over 30 pass-
ages (at least 6 months) even when cultured in medium
without the presence of the selection pressure of
vorinostat. This indicates that vorinostat can induce
stable, that is nonreversible, resistance in HCT116
tumor cells.
Consistent with the clonogenic and growth inhibition
assay data, bright-field microscopy for HCT116 cultures
(Fig. 1c and d) showed that vorinostat treatment
produced a larger reduction in the number of cells and
more dramatic morphological changes (e.g. rounding up)
in cultures with the parental cell line than in those with
the vorinostat-resistant subline (a large fraction retains
its fibroblast-like shape). No morphological differences
between the parental and vorinostat-resistant (untreated)
control cultures were apparent.
Reduced histone acetylation in the
vorinostat-resistant subline
One result of the activity of HDAC inhibitors is the
accumulation of acetylated histones. It was determined
whether the vorinostat-induced resistance with the
HCT116/VOR subline correlated with loss of histone
acetylation. Immunoblot data showed that 15 mmol/l of
vorinostat produced acetylation of the histones H2A,
H2B, H3, and H4 in the parental cell line but not in
the resistant subline (Fig. 2a). p53, tubulin, and HSP90
can also be substrates for HDACs. Vorinostat (15 mmol/l)
produced increases in acetyl-p53 and acetyl-tubulin, but
these increases were similar in the parental HCT116
and the resistant HCT116/VOR cells (Fig. 2a). The
levels of acetylated HSP90 were also comparable in
both cultures and were not affected by vorinostat. These
results indicate that acquired vorinostat resistance
correlates with loss of histone acetylation but not with
alterations in the levels of acetylated p53, tubulin, and
HSP90.
Lack of HDAC overexpression and of MDR expression
in the vorinostat-resistant subline
There are several mechanisms that could give rise to
reduced accumulation of acetylated histones seen
with the vorinostat-resistant subline. These include the
increased availability of HDAC enzymes because of
the overexpression of one or more HDACs or the reduced
availability of intracellular vorinostat because of the
expression of multidrug resistance efflux transporters.
However, immunoblot analysis showed that higher levels
of HDAC1, HDAC2, HDAC3, HDAC5, or HDAC6, were
not found in the vorinostat-resistant subline as com-
pared with its sensitive counterpart (Fig. 2b). HDAC4
and HDAC7 were not detected in both cultures.
Similarly, neither the MDR nor the MRP-1 transporters
were expressed in the parental or resistant cell lines
(Fig. 2c). These results indicate that acquired vorinostat
resistance does neither correlate with expression of
these multidrug resistance transporters nor with over-
expression of HDACs.
Histone acetyltransferase and histone
deacetylase activities
Resistance could arise through alterations in the
enzymatic activities of HATs and HDACs. It was
determined whether the resistant subline exhibits
HAT and HDAC activities that differ from those of
the sensitive cell line; that is whether the HAT activity
was lower and/or the HDAC activity was higher in the
resistant cells. Nuclear HAT activity was similar in the
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resistant HCT116/VOR subline and in the sensitive
HCT116 cell line (Fig. 3a). The enzymatic activities of
HDAC1, HDAC2, HDAC3, and HDAC6 in the resistant
HCT116/VOR subline and the sensitive HCT116 cell
line were comparable and were comparably reduced
by vorinostat (Fig. 3b). According to the activities of
each individual HDAC tested, the overall HDAC activity
was not different in both cultures (Fig. 3c) and was not
differentially affected by vorinostat (Fig. 3d) and by
VPA (data not shown). These results indicate that the
sensitive and the resistant cells are not different with
respect to the HAT and HDAC activities.
Loss of apoptosis and G2/M cell cycle arrest in the
vorinostat-resistant subline
The accumulation of acetylated histones in response to
HDAC inhibitors causes the decondensing of chromatin,
and this facilitates the expression of genes, leading to
an arrest of the cell cycle at the G2/M transition and to
apoptosis. Accordingly, it was determined whether the
loss of histone acetylation seen in the vorinostat-resistant
subline is correlated with the reduced activation of
this cell cycle checkpoint and of apoptosis. Quantitative
analysis of the primary data derived from the flow
cytometry analysis demonstrated that the fraction of cells
Fig. 1
0
0
0
1
1
1
2 2 25 5 5
0
0
0
1
1
1
2 2
2
5 5 5
0
5
10
15
20
25
30
35
48 72 96
Post treatment (h)
R
el
at
iv
e 
gr
ow
th
(b)
0
0.1 1.0
20
40
60
80
100
10.0
μmol/l vorinostat
(a)
S
ur
vi
va
l (
%
)
HCT116
HCT116/VOR
HCT116 HCT116/VOR
C
on
tr
ol
VO
R
(c)
(c′) (d′)
(d)
The effect of the histone deacetylase inhibitor vorinostat (VOR) on clonogenic survival (a) and growth inhibition (b) of the HCT116 colon tumor cell
line and its respective subline (HCT116/VOR, dashed line) generated by stepwise exposures of the HCT116 cells to increasing concentrations of
vorinostat. For the clonogenic assay, cultures were treated with vorinostat for 8 days, and colonies were fixed, stained with Giemsa, and counted
(data points are the mean±SD of at least three independent experiments). For the growth inhibition assay, vorinostat-sensitive cells (black columns)
and vorinostat-resistant cells (grey columns) treated with various concentrations of vorinostat (numbers atop the columns, given in micromole/liter)
were harvested and counted at multiples of 24-h after treatment. Data (mean±SD of two independent experiments) are presented as relative growth
(ratio of the number of cells at a given time point and number of cells initially plated). Representative bright-field images of vorinostat-sensitive
HCT116 (c) and vorinostat-resistant HCT116/VOR (d) control cultures and the respective cultures captured 24h after treatment with 10mmol/l
vorinostat (c0, d0), a large fraction of vorinostat-resistant cells retain their fibroblast-like shape, whereas the vorinostat-sensitive parental cells show
a round-up shape and substantially decrease in number (magnification is 20 and the scale bar equals 50mmol/l).
Acquired resistance to HDAC inhibitors Dedes et al. 325
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
accumulated at the G2/M checkpoint transition was
2.5-fold smaller in the HCT116/VOR subline than in
the parental HCT116 cell line after treatment with
15 mmol/l of vorinostat (Fig. 4a).
Immunoblot analysis (Fig. 4b) showed that 15 mmol/l of
vorinostat failed to produce proteolytic cleavage of the
precursors of caspase 3 and caspase 7 and of the PARP-1
precursor in the resistant subline as compared with
its sensitive counterpart, and TUNEL analysis revealed
that the resistant subline showed a four-fold lower DNA
fragmentation (Fig. 4c). The fraction of Trypan blue-
including cells was nearly the same in untreated cultures
and in cultures treated with 5 or 10 mmol/l of vorinostat
(slightly higher with 20 mmol/l); but there is no difference
between the vorinostat-sensitive cell line and vorinostat-
resistant subline (Fig. 4d), indicating that reduced
susceptibility to necrosis does not account for vorino-
stat-induced resistance. These results indicate that
acquired vorinostat resistance in HCT116 cells cor-
relates with both loss of the G2/M checkpoint and loss
of caspase-dependent apoptosis.
Expression of HDAC inhibitor-responsive and cell
cycle and apoptosis control proteins
HDAC inhibitors affect the expression of a variety
of genes. Among those are proapoptotic Bax and anti-
apoptotic Bcl-2, and the cell cycle regulators p21, p53,
and the cyclins B1, D1, D3, and E. It was determined
whether in the vorinostat-resistant cells the expression of
Bax, p21, and p53 was downregulated and that
of Bcl-2 and the cyclins was upregulated. Immunoblot data
(Fig. 5) showed that expression levels of p21 (and to a
lesser extent p27) were increased upon treatment with
15 mmol/l of vorinostat; but this was to a similar extent in
the resistant and the sensitive cells. The protein levels
of Bax, Bcl-2, and p53 were also similar, Bax and p53 did
not change as a function of time after treatment with
vorinostat, whereas that of Bcl-2 decreased. Similarly,
the expression levels of the cyclins B1, D1, D3, and E2
in the resistant subline did not differ from that in the
sensitive cell line; the expression of B1 and D1 was
downregulated 24 h after vorinostat treatment, whereas
the cyclins D3 and E2 were upregulated. Moreover, the
basal expression level of anti-apoptotic survivin, XIAP, and
Mcl-1 was not increased and that of proapoptotic Bid, Bim,
Bik, and Bok was not decreased in the vorinostat-resistant
subline as compared with the vorinostat-sensitive cell
line. In both cultures, the protein level of XIAP was de-
creased, those of Mcl-1 and Bim were increased, and those
of Bid, Bik, Bok, and survivin were unchanged in response
to vorinostat.
Anti-apoptotic thioredoxin, a protein that scavenges
reactive oxygen species, which can be produced by HDAC
inhibitors, was not overexpressed in the resistant subline,
and thioredoxin-binding protein 2, which downregulates
thioredoxin expression, was not detected. The levels of
HSP90 and phosphorylated HSP27, two heat shock proteins
with cytoprotective functions and reported to be down-
regulated by HDAC inhibition, remained unaffected by
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Histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities determined by in-vitro assay kits. (a) HAT activity expressed as arbitrary
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from HCT116 (black columns) and HCT116/VOR (white columns) extracts. (c) Overall HDAC activity expressed as optical density (OD) per mg of
nuclear extract protein from parental HCT116 and resistant HCT116/VOR cells; also shown are the posititve (HeLa nuclear extract) and the negative
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vorinostat in both cultures. The base level of all these
proteins was comparable in the vorinostat-sensitive and
the vorinostat-resistant cells. These results indicate that
resistance to apoptosis and to cell cycle attenuation in the
vorinostat-induced subline is not reflected by detectable
alterations in the expression of a large number of proteins
usually affected by HDAC inhibitors and relevant to the
control of these processes.
Cross-resistance to other histone deacetylase inhibitors
It was determined whether the HCT116/VOR subline
was cross-resistant to other HDAC inhibitors. A statisti-
cally significant, two-fold to three-fold cross-resistance
was found with VPA (Fig. 6a), LBH589 (Fig. 6b),
JNJ26481585 (Fig. 6c), but not with MGCD0103
(Fig. 6d) and romidepsin (Fig. 6e). The respective IC50
values are presented (Table 1). Accordingly, treatment
with VPA, LBH589 or JNJ26481585 did not result in
accumulation of acetylated histones and cleaved PARP-1
in the vorinostat-resistant subline, whereas the ability to
accumulate acetylated histones and to cleave PARP-1 was
maintained in response to treatment with MGCD0103
and romidepsin.
Acetylated tubulin was essentially expressed to comparable
levels in the vorinostat-resistant and the vorinostat-sensitive
cells. It also looks as though LBH589 and JNJ26481585,
in contrast to VPA, MGCD0103, and romidepsin produced
an increase in acetyl-tubulin to some extent. Acetyl-HSP90
was present in both cultures to the same extent and was
not affected by treatment with each one of the HDAC
inhibitors. These results indicate that acquired resistance
to vorinostat is accompanied by cross-resistance to at least
some HDAC inhibitors, and that cross-resistance does not
go along with alterations in the level of acetylated tubulin
and acetylated HSP90.
No acquisition of resistance by vorinostat in HeLa cells
To determine whether resistance induction by vorinostat
could also be seen with HeLa cells, the same protocol was
Fig. 4
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applied to this tumor cell line. However, this protocol
did not produce a vorinostat-resistant HeLa/VOR subline
and neither loss of accumulation of acetylated histones
nor loss of apoptosis were observed in the subline
(data not shown). This indicates that HeLa cells are not
susceptible to resistance acquisition by vorinostat.
Discussion
The antineoplastic activity of HDAC inhibitors is an
unquestionable property of these compounds; but
recent studies have shed some light on another aspect of
HDAC inhibitors, namely their association with resis-
tance and their potential to cause resistance acquisition
in tumor cells [9–12]. From this study with vorinostat the
following conclusions may be drawn. First, expanding
on a previous study [12], this one provides further evi-
dence that vorinostat has the potential to cause stable and
MDR-independent HDAC inhibitor resistance in vitro.
Second, this acquired resistance clearly correlates with
the losses of histone acetylation, cell cycle checkpoint
activation, and apoptosis susceptibility. Third, this
resistance cannot be explained by altered expression of
selected HDACs, by altered HDAC and HAT activities,
and by failure to induce p21 expression. Fourth,
cross-resistance was found to VPA and hydroxamate-
class HDAC inhibitors, but not to benzamide-class and
cyclic peptide-class HDAC inhibitors. Fifth, using the
parental HCT116 colorectal adenocarcinoma cell line,
this study rules out the possibility that vorinostat
resistance acquisition arises as a consequence of the
presence of extra chromosomes in the chromosome-
supplemented HCT116 cell lines that have been used in
the previous study [12].
The potential of HDAC inhibitors to cause resistance has
recently become apparent. Two studies have shown that
the HDAC inhibitor romidepsin induced a reversible, up
to 10 000-fold resistance in a variety of tumor cells
because of the inducible and transient expressions
of MDR and MRP-1 [10,11]. However, the vorinostat-
induced resistance described here differs from that
with romidepsin in several ways: it is nonreversible (i.e.
was maintained even in the absence of vorinostat in the
culture medium), moderate (two-fold), and cannot be
explained by the efflux of vorinostat through the multi-
drug resistance transporters MDR and MRP-1. The latter
is in line with the observations that MDR-mediated
resistance is usually much greater than two-fold. Our
results thus suggest that resistance acquisition by
vorinostat and by romidepsin are based on the different
mechanisms. Apparently, there is a selection pressure for
vorinostat, beyond which cells are no longer vital. The
observation that this virtually maximal vorinostat concen-
tration (28mmol/l) is substantially higher than the IC50
(1.3 mmol/l) for the vorinostat-resistant HCT116/VOR
subline may mean that there is an at least partial reversal
of vorinostat resistance after removal of the vorinostat
selection pressure in HCT116 cells. A complete reversal
(from 70 mmol/l selection pressure to IC50 1.3 mmol/l) may
be suggested for the HeLa cells.
Acetylation of histones is one hallmark of HDAC
inhibitor-induced cellular responses. Accordingly, acquired
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vorinostat resistance correlated with failure to acetylate
the four histones. Reduced intracellular availability of
vorinostat because of alterations in efflux or influx trans-
porters is unlikely, as MDR transporters are not involved
and there is no evidence that vorinostat is taken up by
processes other than by diffusion. In addition, failure to
acetylate histones may also arise from overexpressed
or overactivated HDACs or from reduced HAT activity
[15], but no lower HAT activity and no higher activity of
individual HDACs (HDAC1, HDAC2, HDAC3, HDAC6)
and of overall HDAC activity were found in the
vorinostat-resistant subline. A previous study has shown
that a truncating mutation in the HDAC2 gene confers
resistance to the HDAC inhibitor trichostatin A [16].
In addition to histones, nonhistone proteins such as
tubulin, p53, and HSP90 are also acetylated as a result
of HDAC inhibitors [17–19]. Acetylated tubulin asso-
ciates with tumor growth inhibition and acetylated
p53 promotes p53-dependent gene transcription
[19,20]. Acetylated HSP90 is inactive and seems to
promote apoptosis [21]. It was reasoned that the vorino-
stat-resistant cells have lower levels of acetylated tubulin,
p53, or HSP90. However, vorinostat induced increases in
acetylated p53 and tubulin in both the sensitive and
resistant cells to a similar extent, and the levels of
acetylated HSP90 remainded unchanged. This indicates
that vorinostat resistance was not accompanied by
reduced acetylation of p53, tubulin, and HSP90.
The therapeutic effect of vorinostat is based on its ability
to produce cell cycle arrest and apoptotic cell death.
Vorinostat targets the G2/M checkpoint in HCT116
tumor cells and the antitumor effect of vorinostat may
be because of induction of polyploidy [22]. This study
shows that the activation of the G2/M checkpoint was
run over and the induction of caspase-dependent
apoptosis was markedly reduced in the vorinostat-
resistant subline. In the vorinostat-resistant subline, the
reduced susceptibility to apoptosis seems to be linked
to the reduced levels of histone acetylation. It was
occasionally observed that vorinostat concentrations,
which induced (reduced with respect to the sensitive
counterpart) apoptosis in the vorinostat-resistant sub-
line, also showed (reduced) accumulation of acetylated
histones, but accumulation of acetylated histones without
apoptosis was never observed. It seems that, at least
for vorinostat, apoptosis does not occur without histone
acetylation, meaning that histone acetylation is required
for vorinostat-induced apoptosis.
It was examined whether alterations in the expression
of a number of cell cycle-relevant genes account for the
observed loss of the G2/M checkpoint activation. However,
alterations in expression of cell cycle-relevant genes were
not observed; p21 expression, which plays a key role in
the cytostatic effect of vorinostat [22], and p27 expression
were observed in both the resistant and the parental cell
line. Cyclin D1 is an HDAC inhibitor-responsive gene and
is downregulated by vorinostat in tumor cells [23]. Indeed,
vorinostat produced downregulation of the cyclins B1 and
D1, but this was also seen in the resistant cells. Similarly,
the HDAC inhibitor-responsive cyclins D3 and E2 were
also upregulated in both cultures.
Reduced apoptosis in the vorinostat-resistant cells may
be because of loss of proapoptotic Bax, Bak, Bid, Bim,
Bik, and Bok; to upregulation of anti-apoptotic Bcl-2, Bcl-
xL [24], Mcl-1, XIAP, and survivin; or to altered
expression of HSP90 and phosphorylated HSP27, two
heat shock proteins downregulated by HDAC inhibitors
[25,26]. This was, however, not the case, as the
expression of these proteins was similar in the vorino-
stat-resistant and in the parental (vorinostat-sensitive)
cells. Similarly, acquired vorinostat resistance cannot be
explained by the increased thioredoxin levels in these cells.
Thioredoxin scavenges reactive oxygen species produced
in response to vorinostat and MS-275 [7], and this results
in the inhibition of oxidative stress-induced cell death [27].
An important finding from this study is that the
vorinostat-resistant cells show cross-resistance to other
‘first-generation’ and ‘second-generation’ HDAC inhibitors,
associated with failure to acetylate histones and to
apoptose in response to these HDAC inhibitors. This is
not only within a particular class of HDAC inhibitors
(the hydroxamates LBH589, JNJ26481585, TSA) but
also among members of different classes of HDAC in-
hibitors (e.g. the aliphatic acid, VPA). A particularly
striking observation was that the vorinostat-resistant
cells retained sensitivity and susceptibility to histone
acetylation and apoptosis to the HDAC inhibitors
MGCD0103 and romidepsin. The benzamide head group
in MGCD0103 and the specific conversion of the cyclic
Table 1 The IC50 values representing cross-resistance of HCT116 and HCT116/VOR cells determined by the clonogenic assay
VPA (mmol/l) JNJ26481585 (nmol/l) LBH589 (nmol/l) MGCD0103 (nmol/l) Romidepsin (nmol/l)
HCT116 1.25±0.11 6.00±1.00 6.27±1.32 241±33 1.07±0.10
HCT116/VOR 2.40±0.13 17.30±0.95 14.4 ±1.10 252±52 1.10±0.10
Fold differencea 1.92 2.88 2.30 1.04 1.03
P values (n=3) <0.001 <0.001 <0.002 0.782 0.716
IC50, half maximal inhibitory concentration; VPA, valproic acid.
aRatio of IC50 values of HCT116/VOR and HCT116.
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peptide romidepsin into its active form [28] seems to make
the difference, as opposed to the hydroxamic acid
(vorinostat, LBH589, JNJ26481585, TSA) or the acid
(VPA) head groups. The absence of cross-resistance to
these two HDAC inhibitors and the previously reported
absence of cross-resistance to ‘classic’ (non-HDAC inhi-
bitor-type) anticancer agents in the vorinostat-resistant
cells may be of clinical interest [12]. Cross-resistance is not
in accord with lower levels of acetylated tubulin nor with
reduced levels of acetylated HSP90. The putative in-
crease in acetylated tubulin in response to LBH589 and
JNJ26481585 (in contrast to VPA, MGCD0103, and
romidepsin) seems to be consistent with the notion that
these two HDAC inhibitors are inhibitors of the tubulin
deacetylase site of HDAC6. In addition, the finding that
HDAC6 activity is comparable in the vorinostat-resistant
and the vorinostat-sensitive cells is consistent with the
comparable level of acetylated tubulin in both cultures.
It is of note that the vorinostat concentrations required
to select for vorinostat resistance in vitro are in the range
of those measured in the serum of patients treated
with therapeutic doses in phase I/II studies [29]. This
may mean that the generation of vorinostat-resistant cells
might also occur in patients. It is somewhat surprising
that in the experimental setting used in this study,
the typical responses to vorinostat, that is, acetylation of
histones and induction of cell cycle arrest and apoptosis,
are observed at relatively high vorinostat concentrations
(15mmol/l), that is, higher than those required to abro-
gate clonogenicity (IC99 around 2 mmol/l). In addition, the
acetylation of histones by vorinostat was detected at later
time points than usual. It is of note that the vorino-
stat-induced responses were essentially also observed
with 5 mmol/l but to a lesser extent.
Despite the clear-cut correlation between acquired
vorinostat resistance and the loss of some molecular
and cellular responses typically seen with HDAC inhi-
bitors, the molecular basis of this resistance is still not
understood. For instance, it is unclear why the effects
of vorinostat on acetylation of nonhistone proteins (e.g.
tubulin, p53, HSP90) and in particular on the expression
of HDAC inhibitor-responsive genes assessed here
(e.g. p21) are similar in the parental (sensitive) and the
resistant cells. It is also unclear how failure to histone
acetylation arises, whether this failure arise from other
HDAC inhibitor sequestration or detoxification systems
or from impaired transport of HDAC inhibitors into
the nucleus, whether DNA methylation, a biochemical
process cooperating with histone (de-)acetylation and
involved in gene silencing [30], is altered at promoter
sites, what may be the role of cellular polyamines [31],
and why resistance acquisition was not observed with
the HeLa cervical cancer cells. Appreciating the com-
plexity of the molecular effects of HDAC inhibitors and
the mechanisms of drug resistance, it is likely that not
one particular mechanism but a multifactorial alteration
of different cell-regulating pathways underlies vorinostat
resistance. This mechanism probably arises because of the
epigenetic targeting by the HDAC inhibitors.
Taken together, this study provides further evidence
for the potential of vorinostat to cause acquisition of
HDAC inhibitor resistance in HCT116 tumor cells. This
acquired HDAC inhibitor resistance clearly correlates
with the loss of important molecular responses typically
seen with HDAC inhibitors and being responsible for
the cytotoxic effect of these compounds.
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